Browse CPE

Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cytoplasmic vesicle, secretory vesicle membrane Peripheral membrane protein Secreted Note=Associated with the secretory granule membrane through direct binding to lipid rafts in intragranular conditions. ; SUBCELLULAR LOCATION: Isoform 2: Nucleus
Domain PF00246 Zinc carboxypeptidase
Function

Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.

> Gene Ontology
 
Biological Process GO:0003007 heart morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003214 cardiac left ventricle morphogenesis
GO:0003231 cardiac ventricle development
GO:0007218 neuropeptide signaling pathway
GO:0007507 heart development
GO:0010817 regulation of hormone levels
GO:0016055 Wnt signaling pathway
GO:0016485 protein processing
GO:0016486 peptide hormone processing
GO:0030070 insulin processing
GO:0042445 hormone metabolic process
GO:0051604 protein maturation
GO:0072657 protein localization to membrane
GO:0198738 cell-cell signaling by wnt
GO:1901142 insulin metabolic process
Molecular Function GO:0004180 carboxypeptidase activity
GO:0004181 metallocarboxypeptidase activity
GO:0004185 serine-type carboxypeptidase activity
GO:0008235 metalloexopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0008238 exopeptidase activity
GO:0017171 serine hydrolase activity
GO:0042043 neurexin family protein binding
GO:0050839 cell adhesion molecule binding
GO:0070008 serine-type exopeptidase activity
Cellular Component GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0043025 neuronal cell body
GO:0044297 cell body
GO:0097060 synaptic membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-264876: Insulin processing
R-HSA-392499: Metabolism of proteins
R-HSA-2980736: Peptide hormone metabolism
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CPE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CPE in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CPE in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.6470.00206
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.3630.208
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1240.434
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0190.97
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1960.918
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1970.929
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1090.852
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0420.978
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.240.889
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8090.702
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7880.581
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.30.0929
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CPE in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CPE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CPE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CPE.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CPE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CPE expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CPE and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCPE
Namecarboxypeptidase E
Aliases carboxypeptidase H; enkephalin convertase; insulin granule-associated carboxypeptidase; cobalt-stimulated ch ......
Chromosomal Location4q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CPE collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CPE.
ID Name Drug Type Targets #Targets
DB00030Insulin HumanBiotechCPE, CTSD, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV, PCSK1, PCSK2, RB1, ......12
DB00071Insulin PorkBiotechCPE, CTSD, HLA-DQA2, HLA-DQB1, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV ......14